LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

University of Miami logo

University of Miami

Status and phase

Terminated
Phase 2

Conditions

Acne
Post Inflammatory Hyperpigmentation

Treatments

Other: Sunscreen
Drug: Liftactiv B3

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05327361
20211099

Details and patient eligibility

About

The purpose of this research study is to measure the depigmenting effect of a serum product called Liftactiv B3 in patients with mild to moderate facial PIHP (Post Inflammatory Hyper Pigmentation)

Enrollment

13 patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Multiethnic subjects
  • 18 to 50 YO
  • Phototype III-VI
  • All skin types
  • 50% with sensitive skin (declarative)
  • Symmetrical mild to moderate facial post-acne PIHP lesions with IGA scale
  • Mild active acne (less than 10 retention and 5 inflammatory lesions)
  • Agreeing not to change their lifestyle during the study period.
  • Capable of reading the documents presented to them, of adhering to the study regulations and accepting the limitations.
  • Available to follow the study
  • Agreeing to participate and having signed the informed consent

Exclusion criteria

  • Moderate to severe active acne
  • Patients under topical or systemic retinoids
  • Patients under systemic immunosuppressants
  • Patients under active treatment of PIHP (including topicals or procedures) within the last 3 months
  • Patients treated with facial procedures within the last 3 months
  • Pregnancy
  • Patient with a recent change in contraception (since less than 6 months)
  • Known allergy to any component of tested product
  • Not presenting with the conditions needed to comply with the protocol.
  • Unable to give their informed consent
  • Not available to follow the study in its entirety

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

13 participants in 2 patient groups

Control Group
Active Comparator group
Description:
Participant will receive sunscreen in the morning and at the beginning of the afternoon for 3 months.
Treatment:
Other: Sunscreen
Liftactiv B3
Experimental group
Description:
Participants will undergo a wash out phase of two weeks where they regularly apply a moisturizer (Hydreane Legere) in the morning and a sunscreen in the morning and at the beginning of the afternoon. On the 3rd week, participants will apply Liftactiv B3 serum daily in the morning before sunscreen and in the evening (two applications daily) on half face for 3 months.
Treatment:
Drug: Liftactiv B3

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems